Advertisement
The first generic version of the EpiPen has been approved by the U.S. Food and Drug Administration

FDA Approves First Generic EpiPen

0
Approval will address both rising costs and shortages of epinephrine
Retrospective review of clinician documentation in the electronic health record can help identify diagnostic uncertainty with moderate reliability

EHR Review Can Measure Diagnostic Uncertainty

0
For more than 70 percent of visits to a primary care clinic, reviewers identified diagnostic uncertainty
Systematic screening for anxiety

Psych Screening Beneficial in Pediatric Abdominal Pain

0
Children with abdominal pain commonly had clinically significant anxiety, moderate disability, pain
A measles outbreak that's so far affected 21 states and the District of Columbia is being investigated by U.S. health officials.

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

0
Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated
A U.S. National Institutes of Health oversight panel will no longer review all applications for gene therapy experiments. Instead

Comments Open on End of NIH Review for Gene Therapy Studies

0
NIH oversight panel no longer plans to review all applications for gene therapy experiments
Practice names and logos should be carefully designed to emphasize what is unique about a practice

Practice Names, Logos Should Be Carefully Designed

0
The logo should be simple and easy to identify, should send a message about the medical practice
Methylphenidate should be considered as a first choice for the treatment of attention-deficit hyperactivity disorder in children and adolescents

Methylphenidate Good First-Choice Pediatric ADHD Drug

0
For adults, amphetamines are reasonable first choice to treat attention-deficit hyperactivity disorder
Brucella canis is an under-recognized infection in dogs that poses a threat to human health

CDC: Brucellosis in Dogs Remains a Public Health Risk

0
Infection is under-recognized, may remain a threat without stronger intervention measures
A U.S. National Institutes of Health oversight panel will no longer review all applications for gene therapy experiments

NIH Panel Will No Longer Review Gene Therapy Experiments

0
FDA will now assess gene therapy experiments and products as it does with other treatments, drugs
Certain steps should be taken when discharging a patient for failure or inability to meet financial obligations

Steps Provided for Discharging Patient From Practice

0
Letter should be sent informing patient of their discharge, providing at least 30 days' notice